KO Client Kiora Pharmaceuticals Partners with Senju

KO client Kiora Pharmaceuticals, a clinical-stage biotechnology company developing advanced therapies for retinal disease, recently announced that it has granted Senju Pharmaceutical Co., Ltd. (Senju) an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic diseases in key Asian marketplaces, including Japan and China.

According to the announcement, this agreement further strengthens Kiora’s balance sheet and supports the Company’s expected cash runway into late 2027, beyond the projected readout of Kiora’s two ongoing Phase 2 clinical trials.

KO partner Brad Schoenfeld was proud to represent Kiora in this agreement. Learn more in Kiora’s announcement and in the Opthalmology Times.